Bioventus BVS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $568.09M-0.9% | $573.28M+11.9% | $512.35M0.0% | $512.12M+18.8% | ||
| $179.93M-2.8% | $185.05M+0.5% | $184.15M+1.7% | $181.04M+41.2% | ||
| $388.16M0.0% | $388.23M+18.3% | $328.19M-0.9% | $331.08M+9.4% | ||
| 68.3%+0.6pp | 67.7%+3.7pp | 64.1%-0.6pp | 64.6%-5.6pp | ||
| $12.11M-13.2% | $13.95M+3.8% | $13.45M-43.6% | $23.85M+25.3% | ||
| $314.03M-8.7% | $343.8M+13.1% | $303.88M-8.5% | $332.13M+30.6% | ||
| $5.73M-25.2% | $7.65M-13.5% | $8.84M-9.3% | $9.75M+16.6% | ||
| —— | -$52K-106% | $911K-86.6% | $6.78M+173% | ||
| $53.98M— | —— | -$82.89M+50.4% | -$167.23M— | ||
| 9.5%— | —— | -16.2%+16.5pp | -32.7%— | ||
| -$26.49M+31.7% | -$38.79M+4.6% | -$40.68M-238% | -$12.02M-981% | ||
| -$28.27M+23.9% | -$37.15M+5.7% | -$39.39M-80.7% | -$21.79M— | ||
| -$81K+72.3% | -$292K+91.8% | -$3.58M— | $0— | ||
| $25.71M+149% | -$52.34M+56.8% | -$121.11M+35.9% | -$189.03M— | ||
| -$1.57M— | —— | —— | -$44.37M-2,157% | ||
| $22.73M+163% | -$36.13M+76.9% | -$156.23M+1.6% | -$158.7M-1,308% | ||
| 4%+10.3pp | -6.3%+24.2pp | -30.5%+0.5pp | -31%-34.0pp | ||
| $0.33+159% | -$0.56+77.7% | -$2.51+2.7% | -$2.58-760% | ||
| $0.34+161% | -$0.56+77.7% | -$2.51+2.7% | -$2.58-760% | ||
| 272.3M+5.9% | 257.2M+2.8% | 250.1M+2.1% | 245M+43.4% | ||
| 266.1M+3.4% | 257.2M+2.8% | 250.1M+2.1% | 245M+43.4% | ||
| -$26.49M+31.7% | -$38.79M+4.6% | -$40.68M-238% | -$12.02M-981% | ||
| $23.41M+159% | -$39.49M+74.6% | -$155.34M+2.3% | -$158.99M-967% | ||
| -$81K+72.3% | -$292K+91.8% | -$3.58M— | $0— | ||
| -$991K— | —— | $0— | —— | ||
| $1.81M+143% | -$4.19M-468% | $1.14M— | —— | ||
| -$21K-61.5% | -$13K-263% | $8K+106% | -$133K-122% | ||
| -$1.45M-188% | $1.65M+27.5% | $1.29M+113% | -$9.77M— | ||
| $568.09M-0.9% | $573.28M+11.9% | $512.35M0.0% | $512.12M+18.8% | ||
| $53.98M+269% | -$31.95M+61.5% | -$82.89M+50.4% | -$167.23M— | ||
| $100.99M+474% | $17.61M+169% | -$25.53M+77.2% | -$111.84M— | ||
| $100.99M+474% | $17.61M+169% | -$25.53M+77.2% | -$111.84M— | ||
| 17.8%+14.7pp | 3.1%+8.1pp | -5%+16.9pp | -21.8%— | ||
| $53.98M+269% | -$31.95M+61.5% | -$82.89M+50.4% | -$167.23M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bioventus's revenue?
- Bioventus (BVS) generated $576.3M in revenue over the trailing twelve months, up 1.5% year over year.
- Is Bioventus profitable?
- Bioventus reported $28.5M in net income over the trailing twelve months, a 4.9% net margin.
- What are Bioventus's profit margins?
- Gross margin is 68.7% and operating margin is 10.0%, with a 4.9% net margin.
- What is Bioventus's earnings per share?
- Bioventus's diluted EPS over the trailing twelve months is $0.41.
- Where does Bioventus's income statement data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
